Open the map

StrykerSYK

Medtech & devices · NYSE · USA

$276.97
Up 0.6% todayClose

Down 21.6% this year and −16.8% since June 26, behind the life science sector at +10.7%. Stryker supplies 1 mapped company.

Market cap
$105B
This year
−21.6%
1 year
−25.4%
P/E
28.0
P/S
4.0
P/B
4.4

Price vs the life science sector

since Jun 26SYKLife science sector, equal weight
Stryker (SYK) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. SYK: −16.8% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.−20%−10%0%+10%Jun 26AugSepOct 8SYK −16.8%Sector +10.7% Stryker (SYK) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. SYK: −16.8% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.−20%−10%0%+10%Jun 26AugSepOct 8SYK−16.8%Sector+10.7%

Supply chain

1 customer
SUPPLIERS →→ CUSTOMERSNone mappedCardinal Health (CAH)CAHCardinal Health+2.9%SYKStryker

Customers 1

Open the full chain →

About Stryker

Orthopaedic implants and surgical equipment, with Mako bringing robot assistance into the operating room.

Theme exposure

MedtechOrthopaedicsSurgical robotics

Products

  • Orthopaedic implants
  • Surgical equipment
  • Robotics (Mako)

Competitors

Risks

  • Procedure volume
  • Acquisition integration

Same segment: Medtech & devices

Medical equipment and devices, from surgery and cardiology to robotics. Segment 7 of 8 in the Medicine, pharma & life science value chain.

Intuitive SurgicalISRG+0.2%MedtronicMDT+2.6%Boston ScientificBSX+1.1%Becton DickinsonBDX+1.4%Edwards LifesciencesEW−1.8%ResMedRMD+0.3%GE HealthCareGEHC−0.7%Zimmer BiometZBH+0.4%

Compare SYK

Side by side with the largest companies in the same segment.

SYK vs ISRGSYK vs MDTSYK vs BSXSYK vs BDXSYK vs EWSYK vs RMD

See where Stryker sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.

Open the Life science value chain →